Market Overview

EyeGate Shares Down 12.5% After Earlier Announcing Top-Line Results For Phase 3 Trial of EGP-437 Showed It Didn't Demonstrate Non-Inferiority To The Control Group; Co. Says It Continues To Review The Data And Assess Options For EGP-437 Going Forward

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: Biotech News FDA General

 

Related Articles (EYEG)

Benzinga's Top Upgrades, Downgrades For September 4, 2018

The Story Of Jack Wu: From 'Transformers' Fan To Robot Creator